RSV Antibody Nirsevimab Cuts Infant Pneumococcal Hospitalizations by 36%
A French study finds babies given the RSV preventive nirsevimab were significantly less likely to be hospitalized for invasive pneumococcal disease.
Summary
A large French study found that infants who received nirsevimab, a monoclonal antibody used to prevent RSV infections, were about 36% less likely to be hospitalized for invasive pneumococcal disease within six months. Researchers analyzed data from babies born in France between February 2023 and January 2024. The protective effect persisted through nine months of follow-up. This suggests that preventing RSV — a common respiratory virus — may also reduce bacterial infections that often follow viral illness. Pneumococcal disease remains dangerous in infants despite available vaccines, partly because new bacterial strains not covered by current vaccines are rising. These findings point to a broader public health value of RSV prevention beyond just RSV itself.
Detailed Summary
Invasive pneumococcal disease, caused by the bacterium Streptococcus pneumoniae, remains a serious and sometimes fatal threat to infants even in countries with robust vaccination programs. Current pneumococcal vaccines cannot cover all bacterial strains, and emerging serotypes are driving renewed increases in cases among young children. Researchers and clinicians have been searching for complementary prevention strategies to close this gap.
A retrospective study published in Lancet Infectious Diseases examined whether nirsevimab — a monoclonal antibody approved to prevent RSV infections in infants — might offer protection against invasive pneumococcal disease as well. Analyzing data from thousands of French babies born between February 2023 and January 2024, the researchers found that infants who received nirsevimab were 36% less likely to be hospitalized for invasive pneumococcal disease over a six-month period. The protective association held at nine months, with a 34% reduction in hospitalization risk.
The proposed mechanism is biological: RSV infection is known to damage airway defenses and may create conditions that allow bacteria like Streptococcus pneumoniae to invade more easily. By blocking RSV, nirsevimab may be indirectly reducing a key viral trigger for bacterial disease. This non-serotype-specific protective pathway is particularly valuable because it would work against pneumococcal strains not targeted by any existing vaccine.
Experts commenting on the study emphasized that current pneumococcal vaccines have likely reached their ceiling of effectiveness, making indirect protective strategies increasingly important. Nirsevimab is already widely used across the US and Europe as standard infant RSV prevention.
Key caveats remain: this was a retrospective observational study, not a randomized trial, meaning residual confounding cannot be fully excluded. Additionally, the maternal RSV vaccine and the newer monoclonal antibody clesrovimab were not part of this French cohort, so their potential spillover effects remain unstudied here.
Key Findings
- Infants receiving nirsevimab were 36% less likely to be hospitalized for invasive pneumococcal disease within 6 months.
- The protective effect persisted at 9 months, with a 34% reduction in pneumococcal hospitalization risk.
- RSV may act as a biological trigger for bacterial pneumococcal invasion, explaining the indirect protection.
- Rising pneumococcal strains not covered by existing vaccines make non-serotype-specific protection strategies critical.
- Experts note current pneumococcal vaccines have likely reached their preventive ceiling, making indirect approaches valuable.
Methodology
This is a news report summarizing a retrospective cohort study published in Lancet Infectious Diseases, a high-credibility peer-reviewed journal. The study analyzed real-world hospitalization data from French infants during the 2023–2024 RSV season. As a retrospective observational design, it cannot establish causation and may be subject to confounding variables.
Study Limitations
The retrospective design limits causal conclusions; unmeasured confounders such as socioeconomic status or healthcare access could influence results. The study was conducted solely in France during one RSV season, limiting generalizability to other populations or seasons. Data on the maternal RSV vaccine and clesrovimab were not available in this cohort, leaving their potential spillover effects unexamined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: